Esperion Targets Seven-Fold Jump in Cholesterol Drug Population with FDA Label Expansion

Esperion secured broader-than-expected FDA labels for its cholesterol-busting drugs Friday, clearing the biotech to target 60 million more patients in the U.S. Shares of the company rose 23% to $2.82 in premarket trading.